Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$296.10 +1.1%	$282.66	$253.30 ▼ $346.85	$158.94B	0.49	2.84 million shs	98,545 shs
BIIB Biogen	$132.28 +1.7%	$127.15	$110.04 ▼ $238.00	$19.32B	0.14	1.43 million shs	63,960 shs
GILD Gilead Sciences	$112.59 +0.7%	$107.12	$66.34 ▼ $119.96	$140.13B	0.29	7.67 million shs	365,624 shs
IONS Ionis Pharmaceuticals	$42.00 +0.5%	$35.48	$23.95 ▼ $52.34	$6.69B	0.23	1.60 million shs	137,935 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-1.78%	+4.92%	+0.90%	+4.53%	-5.77%
BIIB Biogen	-1.88%	+3.61%	-2.25%	+14.10%	-42.33%
GILD Gilead Sciences	+0.45%	+0.82%	-0.60%	+8.32%	+67.61%
IONS Ionis Pharmaceuticals	-2.79%	+5.75%	+18.39%	+63.78%	-9.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.5052 of 5 stars	2.2	2.0	3.3	3.9	4.0	2.5	1.3
BIIB Biogen	4.9175 of 5 stars	4.2	5.0	0.0	3.7	3.2	1.7	1.9
GILD Gilead Sciences	4.8297 of 5 stars	1.4	3.0	4.2	4.1	4.0	2.5	3.1
IONS Ionis Pharmaceuticals	4.6553 of 5 stars	4.4	2.0	0.0	3.0	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.35	Hold	$307.82	5.08% Upside
BIIB Biogen	2.38	Hold	$188.48	44.84% Upside
GILD Gilead Sciences	2.77	Moderate Buy	$111.38	-0.36% Downside
IONS Ionis Pharmaceuticals	2.78	Moderate Buy	$58.25	39.42% Upside

Current Analyst Ratings Breakdown

Latest BIIB, AMGN, GILD, and IONS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	IONS Ionis Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$51.00 ➝ $57.00
6/27/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$328.00
6/26/2025	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$187.00
6/26/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/25/2025	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$205.00 ➝ $213.00
6/24/2025	AMGN Amgen	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/24/2025	AMGN Amgen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$305.00
6/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00
6/12/2025	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$121.00
6/12/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/12/2025	IONS Ionis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$45.00 ➝ $48.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.71	$29.83 per share	9.82	$10.93 per share	26.80
BIIB Biogen	$9.68B	1.97	$22.63 per share	5.75	$114.71 per share	1.13
GILD Gilead Sciences	$28.75B	4.84	$6.87 per share	16.27	$15.44 per share	7.24
IONS Ionis Pharmaceuticals	$717.25M	9.27	N/A	N/A	$3.73 per share	11.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$10.96	26.73	13.70	2.70	17.39%	176.11%	12.39%	8/5/2025 (Estimated)
BIIB Biogen	$1.63B	$10.13	12.85	7.88	1.06	15.07%	14.03%	8.32%	7/30/2025 (Estimated)
GILD Gilead Sciences	$480M	$4.75	23.53	13.78	0.72	20.76%	51.93%	17.40%	8/6/2025 (Estimated)
IONS Ionis Pharmaceuticals	-$453.90M	-$2.99	N/A	N/A	N/A	-63.65%	-91.85%	-15.77%	7/30/2025 (Estimated)

Latest BIIB, AMGN, GILD, and IONS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	AMGN Amgen	$5.21	N/A	N/A	N/A	$8.86 billion	N/A
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/30/2025	Q1 2025	IONS Ionis Pharmaceuticals	-$1.07	-$0.93	+$0.14	-$0.93	$144.31 million	$132.00 million
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.25%	N/A	86.86%	14 Years
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.83%	N/A	66.53%	10 Years
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest BIIB, AMGN, GILD, and IONS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	8.70	1.17	0.88
BIIB Biogen	0.27	1.44	1.01
GILD Gilead Sciences	1.16	1.37	1.23
IONS Ionis Pharmaceuticals	2.63	9.66	9.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BIIB Biogen	87.93%
GILD Gilead Sciences	83.67%
IONS Ionis Pharmaceuticals	93.86%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.69%
BIIB Biogen	0.18%
GILD Gilead Sciences	0.27%
IONS Ionis Pharmaceuticals	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.71 million	534.00 million	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
IONS Ionis Pharmaceuticals	1,069	159.16 million	154.85 million	Optionable

BIIB, AMGN, GILD, and IONS Headlines

Recent News About These Companies

DAVENPORT & Co LLC Sells 6,347 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

July 6 at 4:14 AM | marketbeat.com

Teacher Retirement System of Texas Increases Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

July 5 at 5:22 AM | marketbeat.com

Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last? - Nasdaq

July 5 at 5:18 AM | nasdaq.com

Sumitomo Mitsui Trust Group Inc. Sells 14,224 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

July 5 at 4:10 AM | marketbeat.com

10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know

July 3, 2025 | nasdaq.com

Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross?

July 3, 2025 | zacks.com

Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?

July 3, 2025 | zacks.com

Ionis Pharmaceuticals (NASDAQ:IONS) Trading 7.9% Higher - Here's What Happened

July 2, 2025 | marketbeat.com

Barclays Upgrades Ionis Pharmaceuticals (IONS)

July 2, 2025 | msn.com

Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded at Barclays

July 2, 2025 | americanbankingnews.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 2, 2025 | marketbeat.com

Ionis Pharmaceuticals (NASDAQ:IONS) Rating Increased to Overweight at Barclays

July 1, 2025 | marketbeat.com

Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight

June 29, 2025 | seekingalpha.com

Sovran Advisors LLC Purchases 157,092 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

June 29, 2025 | marketbeat.com

Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results

June 28, 2025 | msn.com

IONS - Ionis Pharmaceuticals Inc Sustainability - Morningstar

June 26, 2025 | morningstar.comM

Salanersen shines in early spinal muscular atrophy research

June 26, 2025 | thepharmaletter.comT

Ionis Pharmaceuticals (NASDAQ:IONS) Given Buy Rating at HC Wainwright

June 26, 2025 | marketbeat.com

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

June 25, 2025 | businesswire.com

IONS - Ionis Pharmaceuticals Inc Executives - Morningstar

June 24, 2025 | morningstar.comM

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire

June 20, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB, AMGN, GILD, and IONS Company Descriptions

Amgen NASDAQ:AMGN

$296.10 +3.15 (+1.08%)

As of 10:17 AM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen NASDAQ:BIIB

$132.28 +2.15 (+1.65%)

As of 10:17 AM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Gilead Sciences NASDAQ:GILD

$112.59 +0.81 (+0.73%)

As of 10:17 AM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Ionis Pharmaceuticals NASDAQ:IONS

$42.00 +0.22 (+0.52%)

As of 10:17 AM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time